Skip to content
Screener

CorMedix CRMD Q3 2025 earnings

Reported November 12, 2025 · Before market open

Revenue$104.3MMiss by $22.7M
EPS$0.57Beat by $0.09
Revenue estimate$127.0M
EPS estimate$0.48

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$53.3M
EPS estimate-$0.10

Financials

Q3 2025

Income statement

See full
Revenue$104.3M+810%
Gross profit$96.7M+794%
Operating income$51.3M+1,662%
Net income$52.6M+1,993%
EPS (diluted)$1.26+2,620%

Balance sheet

See full
Cash & equivalents$49.5M+39.8%
Total debt$5.0M+794%
Total equity$374.1M+537%
Total assets$750.9M+868%

Cash flow

See full
Operating cash flow$30.9M+326%
CapEx$505.9K+5,080%
Free cash flow$30.4M+322%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$868.17M+92.3%
Enterprise value$823.66M+97.8%
P/S4.1×—

Profitability

See full
Gross margin94.4%—
FCF margin34.7%—

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio1.9×-2.0×

Segments

By product

See full
Contract revenue$2.7M—

FAQ

When did CorMedix report Q3 2025 earnings?
CorMedix (CRMD) reported Q3 2025 earnings on November 12, 2025 before market open.
What were CorMedix's Q3 2025 revenue and EPS?
CorMedix reported revenue of $104.3M and eps of $0.57 for Q3 2025.
Did CorMedix beat estimates in Q3 2025?
Revenue missed the consensus estimate of $127.0M by $22.7M. EPS beat the consensus estimate of $0.48 by $0.09.
How did CorMedix's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 810.2% from $11.5M a year earlier.
Where can I find CorMedix's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001213900-25-108716) and the 10-Q periodic report (0001213900-25-108777) directly on SEC EDGAR. The filing index links above go to sec.gov.